Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more - 2Where America’s CO2 emissions come from – what you need to know, in charts
- 3Extraordinary Snowboarding Objections All over the Planet
- 4FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- 5UK can legally stop shadow fleet tankers, ministers believe
- The Response Uncovered: Disentangling the Secrets of the Universe
- Unwind: Four Extraordinary Spa Resorts On the planet
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- Northern lights chances rise for Christmas as space weather remains unsettled
- German economic institutes cut forecast in half over Iran war
- Financial plan Cordial Home Redesigns That Add Worth
- As world leaders enter climate talks, people in poverty have the most at stake
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
